Edwards’ Additional AAA Study Patients May Accelerate FDA Approval
This article was originally published in The Gray Sheet
Executive Summary
Edwards Lifesciences is considering the addition of another 50 patients to a U.S. pivotal trial of the Lifepath abdominal aortic aneurysm (AAA) graft, originally planned to enroll 100 patients by September 2002
You may also be interested in...
Edwards Follows Guidant’s Exit From AAA Market, Seeks Lifepath Acquirer
Edwards Lifesciences' decision to suspend its Lifepath endovascular graft program accompanies a realignment of R&D priorities to cope with the rapidly maturing AAA market
Edwards Follows Guidant’s Exit From AAA Market, Seeks Lifepath Acquirer
Edwards Lifesciences' decision to suspend its Lifepath endovascular graft program accompanies a realignment of R&D priorities to cope with the rapidly maturing AAA market
Edwards Sidesteps Crowded Coronary Stent Field, Targets Peripheral Stents
Edwards Lifesciences' vascular division will focus on peripheral stent technology development for the next few years, foregoing the significantly larger coronary stent market